ACET - Latest News
Adicet Bio, Inc. (ACET), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $81.1M. Beta to the broader market is 1.59.
The article list below shows the most recent ACET headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ACET Headlines
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
zacks.com - Jul 1, 2026
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc.
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
marketbeat.com - Jun 4, 2026
Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conf
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
zacks.com - May 28, 2026
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc.
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
zacks.com - May 25, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 319. 6% in Adicet Bio (ACET).
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
businesswire.com - May 13, 2026
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Adicet Bio, Inc.
How News Affects ACET Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ACET's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ACET news questions
- What is the latest ACET news headline?
- The most recent ACET headline (Jul 1, 2026) is "Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ACET news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ACET news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ACET options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.